Equities

ImmuCell Corp

ImmuCell Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.29
  • Today's Change0.13 / 2.52%
  • Shares traded13.07k
  • 1 Year change+9.07%
  • Beta0.5953
Data delayed at least 15 minutes, as of Mar 27 2024 19:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line, providing Immediate Immunity for the prevention of scours in newborn dairy and beef calves. It expanded this line into four different products with formulations targeting E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. This product line provides Immediate Immunity to newborn calves. The Company is engaged in the development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. The Company’s products reduce the use of traditional antibiotics in food producing animals.

  • Revenue in USD (TTM)17.47m
  • Net income in USD-5.77m
  • Incorporated1987
  • Employees72.00
  • Location
    ImmuCell Corp56 Evergreen DrivePORTLAND 04103United StatesUSA
  • Phone+1 (207) 878-2770
  • Fax+1 (302) 655-5049
  • Websitehttps://immucell.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Singular Genomics Systems Inc2.91m-94.82m38.21m255.00--0.2131--13.12-1.30-1.300.042.420.00980.21823.9411,415.69-31.96---33.80---19.17---3,257.30--9.77--0.0474--280.52---4.34------
Marker Therapeutics Inc3.31m-14.05m38.53m8.00--2.75--11.64-1.59-0.9330.37531.580.1285--1.93413,892.50-54.49-53.74-69.03-62.25-----424.20-1,438.71----0.00---5.7674.2728.97------
SAB Biotherapeutics Inc4.09m-27.21m38.93m56.00--1.45--9.51-5.55-5.550.82642.920.1013--0.632873,122.32-67.32---99.80-------664.53-----66.420.2128---60.73---9.31------
Nymox Pharmaceutical Corp0.00-4.87m39.17m3.00---------0.0536-0.05360.00-0.02040.00-------255.75-264.40---464.48-------13,001.67---42.44--------47.55------
NKGen Biotech Inc0.00-52.37m39.40m-----------3.83-3.830.00-1.860.00-------52.61---66.52-------------0.9041--------559.13------
Fortress Biotech Inc80.97m-84.33m39.88m187.00--1.16--0.4925-12.29-12.2911.511.870.34162.164.43433,000.00-77.03-52.23-140.10-102.3764.9762.90-225.53-281.570.8916-12.491.37--10.1134.44-33.80---7.52--
CASI Pharmaceuticals Inc42.26m-40.42m39.96m224.00--1.39--0.9456-3.00-3.003.152.160.41822.093.49188,678.60-38.41-35.39-66.12-45.3463.84---91.84-211.354.17-26.550.00--42.89---11.90--43.12--
DURECT Corp8.55m-27.62m39.97m72.00--2.70--4.68-1.12-1.120.32580.49560.16240.79273.65---52.47-37.34-124.79-53.4479.9191.83-323.16-139.111.20-55.630.5299---55.67-10.9621.82------
Cyclo Therapeutics Inc1.08m-20.06m40.20m8.00--8.40--37.35-1.33-1.330.06790.16660.12330.38712.14134,551.30-229.72-132.22-727.50-215.1790.8590.37-1,863.35-1,114.041.42-2,769.340.00---21.761.25-29.81---3.95--
ImmuCell Corp17.47m-5.77m41.00m72.00------2.35-0.7454-0.74542.26------------------22.1540.04-33.05-12.64---23.55-----5.909.72-131.57------
Vyne Therapeutics Inc424.00k-27.87m41.73m10.00--0.4703--98.43-6.84-7.000.04136.290.0061--0.163942,400.00-40.27-108.41-45.86-138.57-----6,573.82-1,907.10----0.00---11.11-47.5117.89------
Rapid Micro Biosystems Inc22.52m-52.47m42.07m193.00--0.3558--1.87-1.22-1.220.52342.780.13481.364.07116,678.80-31.41---35.44---24.36---232.99--5.29--0.0026--31.44--13.71------
SensaSure Technologies Inc1.15k-746.37k42.26m1.00------36,749.47-0.0132-0.01320.00002-0.02120.0135--0.79861,150.00-891.64-----------66,024.35-----92.16-----31.15--17.62------
Viracta Therapeutics Inc0.00-51.06m42.41m40.00--3.28-----1.32-1.320.000.46860.00----0.00-66.88-86.35-97.91-106.38-------11,853.94---141.210.5798-------3.78------
Tiziana Life Sciences Ltd - ADR0.00-15.40m42.65m9.00--2.18-----0.1496-0.14960.000.19140.00----0.00-40.89---50.40-------------2,083.710.0183------34.25------
Benson Hill Inc473.34m-111.25m43.26m270.00--0.5028--0.0914-0.5914-0.61312.520.41291.2210.2714.811,753,096.00-28.68---38.28--4.993.18-23.50-40.730.9166-2.330.4509--24.16156.43-11.58--63.78--
Data as of Mar 27 2024. Currency figures normalised to ImmuCell Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.